Company Profiles

driven by the PitchBook Platform

Amylyx Pharmaceuticals

Description

Developer of a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases designed to target the neuroinflammation and nerve cell death that characterize these disorders. The company's proprietary therapeutic AMX0035 is a proprietary combination of existing compounds that have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models, enabling patients suffering from Alzheimer's disease and other neuroinflammation diseases to begin treatment more quickly, resulting in a higher likelihood of a successful treatment.

2014

Founded

PRIVATE

Status

1-10

Employees

Early Stage VC

Latest Deal Type

$1.83M

Latest Deal Amount

$6.83M

Total Amount Raised

Description

Developer of a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases designed to target the neuroinflammation and nerve cell death that characterize these disorders. The company's proprietary therapeutic AMX0035 is a proprietary combination of existing compounds that have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models, enabling patients suffering from Alzheimer's disease and other neuroinflammation diseases to begin treatment more quickly, resulting in a higher likelihood of a successful treatment.

Website:

www.amylyx.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Primary Office

210 Broadway Suite 201 Cambridge, MA 02139United States +1 (617) 571-8872
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Amylyx Pharmaceuticals's full profile, request a free trial.

    Amylyx Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Amylyx Pharmaceuticals Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Amylyx Pharmaceuticals Investors (6)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    ALS Finding a Cure FoundationOtherMinority000 0000000 0000
    ALS Investment FundVenture CapitalMinority000 0000000 0000
    Cure Alzheimer's FundAngel (individual)Minority000 0000000 0000
    Henri TermeerAngel (individual)Minority000 0000000 0000
    Morningside GroupVenture CapitalMinority000 0000000 0000
    ALS Finding a Cure Foundation Other
    ALS Investment Fund Venture Capital
    Cure Alzheimer's Fund Angel (individual)
    Henri Termeer Angel (individual)
    Morningside Group Venture Capital

    Amylyx Pharmaceuticals Executive Team (3)

    NameTitleBoard
    Seat
    Contact
    Info
    Joshua CohenCo-Founder, Chief Executive Officer and Board Member
    Justin KleeCo-Founder, President and Board Member
    Kent LeslieVice President of Research
    Joshua Cohen Co-Founder, Chief Executive Officer and Board Member
    Justin Klee Co-Founder, President and Board Member
    Kent Leslie Vice President of Research

    Amylyx Pharmaceuticals Board Members (6)

    NameRepresentingRoleSinceContact
    Info
    Alan Walts Ph.DSelfBoard Observer & Advisor000 0000
    Felix von CoerperALS Investment FundFund Manager, Investments000 0000
    George MilneAmylyx PharmaceuticalsBoard Member000 0000
    Isaac Cheng MDMorningside GroupInvestor000 0000
    Steve ChubbSelfBoard Member000 0000
    Alan Walts Ph.D Board Observer & Advisor Self
    Felix von Coerper Fund Manager, Investments ALS Investment Fund
    George Milne Board Member Amylyx Pharmaceuticals
    Isaac Cheng MD Investor Morningside Group
    Steve Chubb Board Member Self
    Request full access to PitchBook